- \n
- 0.25 mg or 0.5 mg doses (2 mg pen; 0.68 mg\/mL)\u00a0\u00a0\u00a0\u00a0\u00a0<\/li>\n
- 1 mg doses (4 mg pen; 1.34 mg\/mL)<\/li>\n<\/ul>\n
Apo-Semaglutide Injection\u2122 is administered using a prefilled pen with instructions for use consistent with brand<\/b>\u2011name semaglutide<\/b>, supporting familiarity for patients and health care professionals, facilitating a smooth transition.1<\/p>\n
In Canada, Apo\u2011Semaglutide Injection is indicated for the once\u2011weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise.2<\/p>\n
“The launch of Apo\u2011Semaglutide Injection reflects our Canadian roots and our dedication to making important treatment options more accessible to people across Canada,” said Martin Ar\u00e8s, President, Apotex Canada. “With product now available, we are proud to offer a high\u2011quality, affordable option that supports patients, prescribers, and contributes to a strong and reliable healthcare system for Canadians.”<\/p>\n
Developed in partnership with Orbicular Pharmaceutical Technologies, Apo\u2011Semaglutide Injection underwent Health Canada’s standard regulatory review for peptide medicines.<\/p>\n
For more than five decades, Apotex has played a meaningful role in Canada’s healthcare landscape. By providing high\u2011quality, affordable medicines, the Company helps generate meaningful savings for Canadians and supports broader access to treatment options nationwide.<\/p>\n
Healthcare professionals should consult the complete Product Monograph<\/a> for detailed information on warnings, precautions, adverse reactions, and patient monitoring requirements.<\/p>\n
About Apotex<\/b><\/p>\n
Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more at www.apotex.com<\/a>.<\/p>\n
SOURCE Apotex Inc.<\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=TO60220&Transmission_Id=202605141615PR_NEWS_USPR_____TO60220&DateId=20260514\")
<\/p>\n","protected":false},"excerpt":{"rendered":"TORONTO, May 14, 2026 \/PRNewswire\/ – Apotex Inc. (“Apotex” or the “Company”), the largest Canadian\u2011based global health company,…\n","protected":false},"author":2,"featured_media":960857,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4316],"tags":[268465,105,31571,4348,31572,3732,5489,16,15],"class_list":{"0":"post-960856","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-apotex-inc","9":"tag-health","10":"tag-health-care-hospitals","11":"tag-healthcare","12":"tag-medical-pharmaceuticals","13":"tag-new-products-services","14":"tag-pharmaceuticals","15":"tag-uk","16":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116576901505083166","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/960856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=960856"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/960856\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/960857"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=960856"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=960856"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=960856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}